纳米疫苗结合定制的原位抗PD-L1库用于增强肿瘤免疫治疗。

IF 4.2 2区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Qian Chen PhD , Mengjuan Sun MD , Yanan Li PhD , Liping Huang PhD , Chang Zu PhD , Xiaoqin Kuang BD , Jianing Zhao BD , Mingyu Hao BD , Tingting Ma BD , Chunjiayu Li BD , Jiasheng Tu PhD , Chunmeng Sun PhD , Yunai Du PhD
{"title":"纳米疫苗结合定制的原位抗PD-L1库用于增强肿瘤免疫治疗。","authors":"Qian Chen PhD ,&nbsp;Mengjuan Sun MD ,&nbsp;Yanan Li PhD ,&nbsp;Liping Huang PhD ,&nbsp;Chang Zu PhD ,&nbsp;Xiaoqin Kuang BD ,&nbsp;Jianing Zhao BD ,&nbsp;Mingyu Hao BD ,&nbsp;Tingting Ma BD ,&nbsp;Chunjiayu Li BD ,&nbsp;Jiasheng Tu PhD ,&nbsp;Chunmeng Sun PhD ,&nbsp;Yunai Du PhD","doi":"10.1016/j.nano.2023.102693","DOIUrl":null,"url":null,"abstract":"<div><p><span>Low response rate of immune checkpoint blockade (ICB) has limited its clinical application. A promising strategy to overcome this limitation is the use of therapeutic </span>cancer vaccines<span>, which aim to induce robust immune responses that synergize with ICB through immune enhancement and immune normalization strategies. Herein, we developed a combination immunotherapy<span><span> by combining nano-vaccines consisting of whole tumor cell lysates/CpG liposomes<span> (LCLs) with an anti-PD-L1 loaded lipid gel (aPD-L1@LG). The LCLs were fabricated using cationic liposomes, while the lipid gels (LGs) were prepared by using soybean </span></span>phosphatidylcholine<span><span> (SPC) and glycerol dioleate (GDO). Subcutaneous administration of LCLs successfully activated dendritic cells (DCs), and </span>intratumoral administration<span><span> of anti-PD-L1@LG ensured sustained ICB activity. These results demonstrated that this combination immunotherapy enhanced anti-tumor efficacy and prolonged the survival time in melanoma by activating systemic anti-tumor immune responses. These findings highlight the potential of this rational design as a promising strategy for </span>tumor treatment.</span></span></span></span></p></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Nano-vaccines combining customized in situ anti-PD-L1 depot for enhanced tumor immunotherapy\",\"authors\":\"Qian Chen PhD ,&nbsp;Mengjuan Sun MD ,&nbsp;Yanan Li PhD ,&nbsp;Liping Huang PhD ,&nbsp;Chang Zu PhD ,&nbsp;Xiaoqin Kuang BD ,&nbsp;Jianing Zhao BD ,&nbsp;Mingyu Hao BD ,&nbsp;Tingting Ma BD ,&nbsp;Chunjiayu Li BD ,&nbsp;Jiasheng Tu PhD ,&nbsp;Chunmeng Sun PhD ,&nbsp;Yunai Du PhD\",\"doi\":\"10.1016/j.nano.2023.102693\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span>Low response rate of immune checkpoint blockade (ICB) has limited its clinical application. A promising strategy to overcome this limitation is the use of therapeutic </span>cancer vaccines<span>, which aim to induce robust immune responses that synergize with ICB through immune enhancement and immune normalization strategies. Herein, we developed a combination immunotherapy<span><span> by combining nano-vaccines consisting of whole tumor cell lysates/CpG liposomes<span> (LCLs) with an anti-PD-L1 loaded lipid gel (aPD-L1@LG). The LCLs were fabricated using cationic liposomes, while the lipid gels (LGs) were prepared by using soybean </span></span>phosphatidylcholine<span><span> (SPC) and glycerol dioleate (GDO). Subcutaneous administration of LCLs successfully activated dendritic cells (DCs), and </span>intratumoral administration<span><span> of anti-PD-L1@LG ensured sustained ICB activity. These results demonstrated that this combination immunotherapy enhanced anti-tumor efficacy and prolonged the survival time in melanoma by activating systemic anti-tumor immune responses. These findings highlight the potential of this rational design as a promising strategy for </span>tumor treatment.</span></span></span></span></p></div>\",\"PeriodicalId\":19050,\"journal\":{\"name\":\"Nanomedicine : nanotechnology, biology, and medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nanomedicine : nanotechnology, biology, and medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1549963423000448\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine : nanotechnology, biology, and medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1549963423000448","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 1

摘要

免疫检查点阻断(ICB)的低应答率限制了其临床应用。克服这一限制的一个有前景的策略是使用治疗性癌症疫苗,其目的是通过免疫增强和免疫正常化策略诱导与ICB协同作用的强大免疫反应。在此,我们开发了一种联合免疫疗法,将由全肿瘤细胞裂解物/CpG脂质体(LCLs)组成的纳米疫苗与负载抗PD-L1的脂质凝胶相结合(aPD-L1@LG)。使用阳离子脂质体制备LCL,而使用大豆磷脂酰胆碱(SPC)和甘油二醇酯(GDO)制备脂质凝胶(LGs)。LCLs皮下给药成功激活树突状细胞(DC),肿瘤内给药anti-PD-L1@LG确保了持续的洲际弹道导弹活动。这些结果表明,这种联合免疫疗法通过激活全身抗肿瘤免疫反应,增强了黑色素瘤的抗肿瘤疗效并延长了生存时间。这些发现突出了这种合理设计作为一种有前途的肿瘤治疗策略的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Nano-vaccines combining customized in situ anti-PD-L1 depot for enhanced tumor immunotherapy

Nano-vaccines combining customized in situ anti-PD-L1 depot for enhanced tumor immunotherapy

Low response rate of immune checkpoint blockade (ICB) has limited its clinical application. A promising strategy to overcome this limitation is the use of therapeutic cancer vaccines, which aim to induce robust immune responses that synergize with ICB through immune enhancement and immune normalization strategies. Herein, we developed a combination immunotherapy by combining nano-vaccines consisting of whole tumor cell lysates/CpG liposomes (LCLs) with an anti-PD-L1 loaded lipid gel (aPD-L1@LG). The LCLs were fabricated using cationic liposomes, while the lipid gels (LGs) were prepared by using soybean phosphatidylcholine (SPC) and glycerol dioleate (GDO). Subcutaneous administration of LCLs successfully activated dendritic cells (DCs), and intratumoral administration of anti-PD-L1@LG ensured sustained ICB activity. These results demonstrated that this combination immunotherapy enhanced anti-tumor efficacy and prolonged the survival time in melanoma by activating systemic anti-tumor immune responses. These findings highlight the potential of this rational design as a promising strategy for tumor treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.10
自引率
0.00%
发文量
133
审稿时长
42 days
期刊介绍: The mission of Nanomedicine: Nanotechnology, Biology, and Medicine (Nanomedicine: NBM) is to promote the emerging interdisciplinary field of nanomedicine. Nanomedicine: NBM is an international, peer-reviewed journal presenting novel, significant, and interdisciplinary theoretical and experimental results related to nanoscience and nanotechnology in the life and health sciences. Content includes basic, translational, and clinical research addressing diagnosis, treatment, monitoring, prediction, and prevention of diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信